Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in AKR?
Akers Biosciences, Inc.: THE INVESTMENT CASE

Akers Biosciences upbeat on prospects; Heparin allergy test will bolster growth

PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Akers Biosciences upbeat on prospects; Heparin allergy test will bolster growth
INVESTMENT OVERVIEW: AKR The Big Picture
The numbers are starting to add up for Akers

Akers Biosciences Inc. (NASDAQ:AKER) (LON:AKR) reported a 40% increase in full year revenue, boosted by sales of its flagship Heparin allergy test.

Total revenue rose to US$2.9mln in the year to 31 December 2016, compared to US$2.1mln the previous year.

PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales to US$2.6mln from US$1.4mln.

Akers said it hit record sales of PF/4 products in the US in the second half. The group also significantly raised the price of the products.

A three-year agreement was signed to introduce PF/4 to the Greater New York Hospital Association’s network of more than 300 member hospitals and health systems

As revenues jumped and the company cut costs, the loss from operations narrowed to US$3.3mln in 2016 from US$9.3mln the prior year.

On another positive note for the group, Akers has won its first order for its rapid, over-the-counter cholesterol self-test.

Distribution 

First Check Diagnostics, the exclusive distributor in the US, will sell it under its "First Check" brand, through retailers such as CVS, Rite Aid, Target, Kmart and others.

The test estimates good cholesterol or High Density Lipoprotein (HDL) levels and can differentiate this from a person's Low Density Lipoprotein, their 'bad cholesterol'.

Meanwhile, Akers has completed successful trials for BreathScan DKA, a rapid breath test for diabetic ketoacidosis. It has also had positive trials for the PIFA/Chlamydia Rapid Assay, a rapid blood test for chlamydia, and for a rapid breath test for oxidative stress called BreathScan OxiCheck.

Akers chief executive, John Gormally, said: “I expect 2017 to be characterised by further growth in our flagship PIFA Heparin PF/4 Rapid Assay product line, sales of our rapid cholesterol test direct to consumers through major US retailers under the First Check brand, growing sales from our new generation of app-connected wellness products and, subject to regulatory approvals, the launch into the market of the first rapid blood test for chlamydia and a breath test for nutritional ketosis or fat burning.”

Extension 

The company has applied for a 15-day extension to file its Form 10-K containing its 2016 earnings. Doing so will allow time for the company and its auditors to incorporate data from “certain subsequent events” and complete “management discussion and analysis”,  Akers said.

“We look forward to publishing our Form 10-K earnings statement in due course,” Gormally said. 



Register here to be notified of future AKR Company articles
View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

Related Articles

Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use